3 results
To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered by grass pollen.
The study contains 2 parts: Part 1 is the dose escalation part. Part 2 is the dose expansion part.The primary objective of part 1 is to determine recommended Phase 2 dose(s) (RP2Ds) of JNJ-78278343 by investigating the incidence and severity of AEs…
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…